Shattuck Labs Announces Phase 2 Trial and New SVP of Clinical Development

Shattuck Labs Inc. announced its Phase 2 clinical trial for SL-325 in hidradenitis suppurativa and the appointment of Shoba Ravichandran, M.D., as Senior Vice President of Clinical Development.